新型冠狀病毒

Chinese Covid jab makers hit after US backs plan to halt patents

Shares in CanSino and Fosun Pharma tumble on prospect of jump in global vaccine supply

Shares in Chinese makers of Covid-19 vaccines tumbled after Washington backed a proposal to temporarily suspend intellectual property rights for the jabs.

In afternoon trading on Thursday, Fosun Pharma lost 9 per cent, CanSino Biologics 14 per cent and Walvax Biotechnology 10 per cent. ChiNext, a tech-focused index of companies listed in Shenzhen, fell 2.2 per cent while the broader CSI 300 of China’s biggest stocks dropped 1.1 per cent.

The market moves underscored the international repercussions of the US announcement on Wednesday, which stands to increase the global supply of vaccines.

您已閱讀26%(593字),剩餘74%(1712字)包含更多重要資訊,訂閱以繼續探索完整內容,並享受更多專屬服務。
版權聲明:本文版權歸FT中文網所有,未經允許任何單位或個人不得轉載,複製或以任何其他方式使用本文全部或部分,侵權必究。
設置字型大小×
最小
較小
默認
較大
最大
分享×